Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer
NCT02076594 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 171
Last updated 2019-10-09
Summary
This is a randomized, parallel group, non-blinded phase III trial. Patients with advanced (locoregional or metastatic) gastric cancer not previously treated with chemotherapy for this stage will be randomized in a 1:1 ratio to receive low-TOX (arm A) or EOX (arm B). Randomization will be stratified by performance status (ECOG 0, 1 and 2).
Conditions
- Locally Advanced Unresectable Gastric Cancer
- Metastatic Gastric Cancer
Interventions
- DRUG
-
Powder for solution for infusion
- DRUG
-
Epirubicin
Solution for infusion
- DRUG
-
Powder for solution for infusion
- DRUG
-
Film coated tablets
Sponsors & Collaborators
-
Regione Lombardia
collaborator OTHER -
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
lead OTHER
Principal Investigators
-
Roberto Labianca, MD · A.O. Papa Giovanni XXIII di Bergamo, Oncologia Medica
-
Enrico Cortesi, MD · Policlinico Umbero I di Roma, UOC Oncologia Medica B
-
Domenico Cristiano Corsi, MD · Ospedale Fatebenefratelli di Roma, Oncologia
-
Pietro Sozzi, MD · Ospedale degli Infermi di Biella, Oncologia
-
Luigi Cavanna, MD · AUSL di Piacenza, Oncologia Medica
-
Domenico Bilancia, MD · A.O. Ospedale San Carlo di Potenza, Oncologia Medica
-
Rosa Rita Silva, MD · ASUR Zona 6 di Fabriano, Oncologia
-
Nicola Fazio, MD · IRCCS Istituto Europeo di Oncologia di Milano, Tumori digestivi superiori e Neuroendocrini
-
Monica Giordano, MD · A. O. Sant'Anna di Como, Oncologia
-
Alessandro Bertolini, MD · Ospedale Civile di Sondrio, Oncologia Medica
-
Giovanni Ucci, MD · A.O. Ospedale Maggiore di Lodi, Oncologia
-
Donato Natale, MD · A.O. di Pescara - Oncologia
-
Daris Ferrari, MD · A.O. San Paolo di Milano, Oncologia Medica
-
Graziella Pinotti, MD · Ospedale di Circolo e Fondazione Macchi di Varese, Oncologia
-
Ermanno Rondini, MD · Ospedale di S. Maria Nuova di Reggio Emilia, Oncologia Medica
-
Massimo Cirillo, MD · Ospedale Sacro Cuore Don Calabria di Negrar, Oncologia Medica
-
Rosario Vincenzo Iaffaioli, MD · IRCCS Istituto Nazionale Tumori Fondazione Pascale di Napoli, Oncologia Medica Addominale
-
Andrea Ciarlo, MD · Ospedale Misericordia e Dolce di Prato, Oncologia Medica
-
Elena Piazza, MD · Ospedale L. Sacco di Milano, Oncologia
-
Libero Ciuffreda, MD · Azienda Ospedaliera Città della Salute e della Scienza di Torino, Oncologia Medica
-
Stefania Dell'Oro, MD · Ospedale di Circolo A. Manzoni di Lecco, Oncologia Medica
-
Fabrizio Artioli, MD · Ospedale di Carpi, Medicina Oncologica
-
Claudio Verusio, MD · Ospedale Generale Provinciale di Saronno, Oncologia Medica
-
Vincenzo Catalano, MD · A.O. Ospedali Riuniti Marche Nord - Presidio S. Salvatore Muraglia, Oncologia
-
Claudio Graiff, MD · ASDAA Bolzano, Oncologia Medica
-
Domenico Amoroso, MD · A.O. Ospedale Versilia di Camaiore, Oncologia Medica
-
Maria Di Bartolomeo, MD · Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Medicina Oncologica 1
-
Nicola Silvestris, MD · Istituto Tumori di Bari, Oncologia Medica
-
Maria C. Zavettieri, MD · OSPED. DI CIRCOLO SERBELLONI-GORGONZOLA - GORGONZOLA (MI)
-
Enzo Veltri, MD · OSPEDALE SANTA MARIA GORETTI LATINA
-
Francesco Ferraù, MD · P.O. "SAN VINCENZO" TAORMINA - TAORMINA (ME)
-
Giampaolo Tortora, MD · OSPEDALE POLICLINICO G.B. ROSSI (BORGO ROMA) DI VERONA
-
Sandro Barni, MD · A.O. TREVIGLIO-CARAVAGGIO - TREVIGLIO (BG)
-
Mario Scartozzi, MD · A.O.U. di Cagliari - Presidio di Monserrato
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-01-31
- Primary Completion
- 2018-12-31
- Completion
- 2018-12-31
Countries
- Italy
Study Locations
More Related Trials
-
Docetaxel and Epirubicin as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma of the Stomach
NCT00075465 ·Status: UNKNOWN ·Phase: PHASE2
-
The Maintenance Therapy of Capecitabine of Advanced Gastric Cancer
NCT02038621 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficiency of XELOX Neoadjuvant Chemotherapy in Gastric Cancer
NCT01665274 ·Status: TERMINATED ·Phase: PHASE2
-
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
NCT07001748 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Docetaxel and Epirubicin in Advanced Gastric Cancer
NCT00375999 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Advanced Gastric Cancer (AGC)
NCT00743964 ·Status: COMPLETED ·Phase: PHASE2
-
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer
NCT00719550 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer
NCT01471470 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma
NCT05008783 ·Status: COMPLETED ·Phase: PHASE3
-
Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma
NCT01351038 ·Status: TERMINATED ·Phase: PHASE2
-
ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction
NCT01234324 ·Status: COMPLETED ·Phase: PHASE2
-
Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients
NCT00952003 ·Status: COMPLETED ·Phase: PHASE2
-
Docetaxel and Capecitabine in Advanced Gastric Cancer
NCT00142038 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer
NCT05980481 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
NCT00813072 ·Status: COMPLETED ·Phase: PHASE2
-
Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer
NCT01470742 ·Status: WITHDRAWN ·Phase: PHASE3
-
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT05702229 ·Status: RECRUITING ·Phase: PHASE2
-
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
NCT01697072 ·Status: TERMINATED ·Phase: PHASE3
-
Compare Neoadjuvant Chemotherapy of DOS Versus SOX in Locally Advanced Gastric Adenocarcinoma.
NCT03691454 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer
NCT01364493 ·Status: COMPLETED ·Phase: PHASE2
-
Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage Ⅲ Clinical Study
NCT02555358 ·Status: COMPLETED ·Phase: PHASE2
-
Oxaliplatin and S-1 or Oxaliplatin and Capecitabine in Treating Patients With Recurrent, Metastatic, or Unresectable Gastric Cancer
NCT00985556 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates
NCT00130936 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer
NCT01748773 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
NCT04933227 ·Status: TERMINATED ·Phase: PHASE2